A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis

Journal of Clinical Medicine

Volumn 6, Issue 1, 2017, Pages

  Betensley, Alan ^a   Sharif, Rabab ^b   Karamichos, Dimitrios ^b  

^a INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic lung allograft dysfunction; Extracellular matrix remodeling; Idiopathic pulmonary fibrosis; Lung transplantation

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; NINTEDANIB; PIRFENIDONE;

ABDOMINAL DISTENSION; ANTICOAGULATION; BLOOD CLOTTING; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; DIARRHEA; DISEASE COURSE; DIZZINESS; EPIGENETICS; EXTRACELLULAR MATRIX; FORCED VITAL CAPACITY; GRAFT DYSFUNCTION; HOMEOSTASIS; HUMAN; IDIOPATHIC DISEASE; IMMUNOSTIMULATION; INFLAMMATION; INSOMNIA; LUNG FIBROSIS; LUNG INJURY; LUNG TRANSPLANTATION; MULTICENTER STUDY (TOPIC); MYOFIBROBLAST; NAUSEA; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PREVALENCE; PROGNOSIS; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SYSTEMATIC REVIEW; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 85067220110     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6010002     Document Type: Review

References (105)

1. Velnar, T., Bailey, T., Smrkolj, V. The wound healing process: An overview of the cellular and molecular mechanisms. J. Int. Med. Res. 2009, 37, 1528-1542.
2. Loots, M.A., Lamme, E.N., Zeegelaar, J., Mekkes, J.R., Bos, J.D., Middelkoop, E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J. Investig. Dermatol. 1998, 111, 850-857.
3. Rodero, M.P., Khosrotehrani, K. Skin wound healing modulation by macrophages. Int. J. Clin. Exp. Pathol. 2010, 3, 643-653.
4. Gosain, A., DiPietro, L.A. Aging and wound healing. World J. Surg. 2004, 28, 321-326.
5. Tamama, K., Kerpedjieva, S.S. Acceleration of wound healing by multiple growth factors and cytokines secreted from multipotential stromal cells/mesenchymal stem cells. Adv. Wound Care 2012, 1, 177-182.
6. Barrientos, S., Brem, H., Stojadinovic, O., Tomic-Canic, M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen. 2014, 22, 569-578.
7. Gurtner, G.C., Werner, S., Barrandon, Y., Longaker, M.T. Wound repair and regeneration. Nature 2008, 453, 314-321.
8. Wilgus, T.A., Roy, S., McDaniel, J.C. Neutrophils and wound repair: Positive actions and negative reactions. Adv. Wound Care 2013, 2, 379-388.
9. Mittal, M., Siddiqui, M.R., Tran, K., Reddy, S.P., Malik, A.B. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 2014, 20, 1126-1167.
10. Guo, S., DiPietro, L.A. Factors affecting wound healing. J. Dent. Res. 2010, 89, 219-229.
11. Borthwick, L.A., Corris, P.A., Mahida, R., Walker, A., Gardner, A., Suwara, M., Johnson, G.E., Moisey, E.J., Brodlie, M., Ward, C., et al. Tnfalpha from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. Am. J. Transplant. 2013, 13, 621-633.
12. Herrera, I., Cisneros, J., Maldonado, M., Ramirez, R., Ortiz-Quintero, B., Anso, E., Chandel, N.S., Selman, M., Pardo, A. Matrix metalloproteinase (mmp)-1 induces lung alveolar epithelial cell migration and proliferation, protects from apoptosis, and represses mitochondrial oxygen consumption. J. Biol. Chem. 2013, 288, 25964-25975.
13. Dancer, R.C.A., Wood, A.M., Thickett, D.R. Metalloproteinases in idiopathic pulmonary fibrosis. Eur. Respir. J. 2011, 38, 1461-1467.
14. Clarke, D.L., Carruthers, A.M., Mustelin, T., Murray, L.A. Matrix regulation of idiopathic pulmonary fibrosis: The role of enzymes. Fibrogenesis Tissue Repair 2013, 6, 20.
15. González-López, A., Albaiceta, G.M. Repair after acute lung injury: Molecular mechanisms and therapeutic opportunities. Crit. Care 2012, 16, 209.
16. Crosby, L.M., Waters, C.M. Epithelial repair mechanisms in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298, L715-L731.
17. Meltzer, E.B., Noble, P.W. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 2008, 3, 8.
18. Fernandez, I.E., Heinzelmann, K., Verleden, S., Eickelberg, O. Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. Ann. Am. Thorac. Soc. 2015, 12, S34-S41.
19. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.-F., Flaherty, K.R., Lasky, J.A., et al. An official ats/ers/jrs/alat statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788-824.
20. Scott, J., Johnston, I., Britton, J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 1990, 301, 1015-1017.
21. Iwai, K., Mori, T., Yamada, N., Yamaguchi, M., Hosoda, Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994, 150, 670-675.
22. Ley, B., Collard, H.R. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 2013, 5, 483-492.
23. Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., Esser, D. Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. Eur. Respir. Rev. 2012, 21, 355-361.
24. Hubbard, R., Lewis, S., Richards, K., Johnston, I., Britton, J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet (London, England) 1996, 347, 284-289.
25. Behr, J. The diagnosis and treatment of idiopathic pulmonary fibrosis. Deutsches Ärzteblatt Int. 2013, 110, 875-881.
26. Coultas, D.B., Zumwalt, R.E., Black, W.C., Sobonya, R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994, 150, 967-972.
27. Fernandez Perez, E.R., Daniels, C.E., Schroeder, D.R., St Sauver, J., Hartman, T.E., Bartholmai, B.J., Yi, E.S., Ryu, J.H. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study. Chest 2010, 137, 129-137.
28. Kolek, V. Epidemiology of cryptogenic fibrosing alveolitis in moravia and silesia. Acta Univ. Palacki. Olomuc. Fac. Med. 1994, 137, 49-50.
29. Hodgson, U., Laitinen, T., Tukiainen, P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: Evidence of founder effect among multiplex families in finland. Thorax 2002, 57, 338-342.
30. Karakatsani, A., Papakosta, D., Rapti, A., Antoniou, K.M., Dimadi, M., Markopoulou, A., Latsi, P., Polychronopoulos, V., Birba, G., Ch, L., et al. Epidemiology of interstitial lung diseases in greece. Respir. Med. 2009, 103, 1122-1129.
31. Gribbin, J., Hubbard, R.B., Le Jeune, I., Smith, C.J., West, J., Tata, L.J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006, 61, 980-985.
32. Navaratnam, V., Fleming, K.M., West, J., Smith, C.J., Jenkins, R.G., Fogarty, A., Hubbard, R.B. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011, 66, 462-467.
33. Lai, C.C., Wang, C.Y., Lu, H.M., Chen, L., Teng, N.C., Yan, Y.H., Wang, J.Y., Chang, Y.T., Chao, T.T., Lin, H.I., et al. Idiopathic pulmonary fibrosis in taiwan—A population-based study. Respir. Med. 2012, 106, 1566-1574.
34. Ohno, S., Nakaya, T., Bando, M., Sugiyama, Y. Idiopathic pulmonary fibrosis—Results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology (Carlton, Victoria) 2008, 13, 926-928.
35. Meuret, G., Fueter, R., Gloor, F. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone. Respir. Int. Rev. Thorac. Dis. 1978, 36, 228-233.
36. Raghu, G., Depaso, W.J., Cain, K., Hammar, S.P., Wetzel, C.E., Dreis, D.F., Hutchinson, J., Pardee, N.E., Winterbauer, R.H. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991, 144, 291-296.
37. Rochwerg, B., Schünemann, H.J., Raghu, G. Idiopathic pulmonary fibrosis—Clinical management guided by the evidence-based grade approach: What arguments can be made against transparency in guideline development? BMC Med. 2016, 14, 22.
38. Meyer, K.C. Diagnosis and management of interstitial lung disease. Transl. Respir. Med. 2014, 2, 4.
39. King, T.E. Nonspecific interstitial pneumonia and systemic sclerosis. Am. J. Respir. Crit. Care Med. 2002, 165, 1578-1579.
40. Tansey, D., Wells, A.U., Colby, T.V., Ip, S., Nikolakoupolou, A., du Bois, R.M., Hansell, D.M., Nicholson, A.G. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004, 44, 585-596.
41. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. Am. J. Respir. Crit. Care Med. 2000, 161, 646-664.
42. Verleden, S.E., Todd, J.L., Sato, M., Palmer, S.M., Martinu, T., Pavlisko, E.N., Vos, R., Neyrinck, A., Van Raemdonck, D., Saito, T., et al. Impact of clad phenotype on survival after lung retransplantation: A multicenter study. Am. J. Transplant. 2015, 15, 2223-2230.
43. Kaarteenaho, R. The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir. Res. 2013, 14, 43.
44. Maher, T.M. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barcelona, Spain) 2010, 46, 473-482.
45. Cottin, V., Maher, T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2015, 24, 58-64.
46. Fala, L. Ofev (nintedanib): First tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis. Am. Health Drug Benefits 2015, 8, 101-104.
47. Gross, T.J., Hunninghake, G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001, 345, 517-525.
48. Egan, J.J. Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient. Eur. Respir. Rev. 2011, 20, 114-117.
49. Adamali, H.I., Anwar, M.S., Russell, A.-M., Egan, J.J. Non-pharmacological treatment of idiopathic pulmonary fibrosis. Curr. Respir. Care Rep. 2012, 1, 208-215.
50. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002, 165, 277-304.
51. Martinez, F.J., Flaherty, K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006, 3, 315-321.
52. Christie, J.D., Edwards, L.B., Kucheryavaya, A.Y., Benden, C., Dipchand, A.I., Dobbels, F., Kirk, R., Rahmel, A.O., Stehlik, J., Hertz, M.I. The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012. J. Heart Lung Transplant. 2012, 31, 1073-1086.
53. Hartert, M., Senbaklavaci, Ö., Gohrbandt, B., Fischer, B.M., Buhl, R., Vahl, C.-F. Lung transplantation: A treatment option in end-stage lung disease. Deutsches Ärzteblatt Int. 2014, 111, 107-116.
54. Spagnolo, P., Tonelli, R., Cocconcelli, E., Stefani, A., Richeldi, L. Idiopathic pulmonary fibrosis: Diagnostic pitfalls and therapeutic challenges. Multidiscip. Respir. Med. 2012, 7, 42.
55. Tzouvelekis, A., Bonella, F., Spagnolo, P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther. Clin. Risk Manag. 2015, 11, 359-370.
56. Tulek, B., Kiyan, E., Toy, H., Kiyici, A., Narin, C., Suerdem, M. Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats. Clin. Investig. Med. 2011, 34, E341.
57. Myllärniemi, M., Kaarteenaho, R. Pharmacological treatment of idiopathic pulmonary fibrosis—Preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur. Clin. Respir. J. 2015.
58. Ahluwalia, N., Shea, B.S., Tager, A.M. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am. J. Respir. Crit. Care Med. 2014, 190, 867-878.
59. Misumi, S., Lynch, D.A. Idiopathic pulmonary fibrosis/usual interstitial pneumonia. Proc. Am. Thorac. Soc. 2006, 3, 307-314.
60. Luppi, F., Cerri, S., Beghè, B., Fabbri, L.M., Richeldi, L. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir. Med. 2004, 98, 1035-1044.
61. Crooks, M.G., Hart, S.P. Coagulation and anticoagulation in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2015, 24, 392-399.
62. Wilson, M.S., Wynn, T.A. Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal Immunol. 2009, 2, 103-121.
63. Chambers, R.C. Abnormal wound healing responses in pulmonary fibrosis: Focus on coagulation signalling. Eur. Respir. Rev. 2008, 17, 130-137.
64. Juarez, M.M., Chan, A.L., Norris, A.G., Morrissey, B.M., Albertson, T.E. Acute exacerbation of idiopathic pulmonary fibrosis—A review of current and novel pharmacotherapies. J. Thorac. Dis. 2015, 7, 499-519.
65. Huan, C., Yang, T., Liang, J., Xie, T., Cheng, L., Liu, N., Kurkciyan, A., Monterrosa Mena, J., Wang, C., Dai, H., et al. Methylation-mediated bmper expression in fibroblast activation in vitro and lung fibrosis in mice in vivo. Sci. Rep. 2015, 5, 14910.
66. Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K.E., Stowasser, S., Kolb, M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015, 45, 1434-1445.
67. Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071-2082.
68. Lehtonen, S.T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M.C., Kaarteenaho, R. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir. Res. 2016, 17, 1-12.
69. Kreuter, M., Bonella, F., Wijsenbeek, M., Maher, T.M., Spagnolo, P. Pharmacological treatment of idiopathic pulmonary fibrosis: Current approaches, unsolved issues, and future perspectives. BioMed Res. Int. 2015, 2015, 10.
70. Cho, M.E., Kopp, J.B. Pirfenidone: An anti-fibrotic and cytoprotective agent as therapy for progressive kidney disease. Expert Opin. Investig. Drugs 2010, 19, 275-283.
71. Iyer, S.N., Wild, J.S., Schiedt, M.J., Hyde, D.M., Margolin, S.B., Giri, S.N. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 1995, 125, 779-785.
72. Gan, Y., Herzog, E.L., Gomer, R.H. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther. Clin. Risk Manag. 2011, 7, 39-47.
73. Kolilekas, L., Manali, E., Vlami, K.A., Lyberopoulos, P., Triantafillidou, C., Kagouridis, K., Baou, K., Gyftopoulos, S., Vougas, K.N., Karakatsani, A., et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J. Clin. Sleep Med. 2013, 9, 593-601.
74. Ozalevli, S., Karaali, H.K., Ilgin, D., Ucan, E.S. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip. Respir. Med. 2010, 5, 31-37.
75. Miki, K., Maekura, R., Hiraga, T., Okuda, Y., Okamoto, T., Hirotani, A., Ogura, T. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir. Med. 2003, 97, 482-490.
76. Sakai, N., Tager, A.M. Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim. Biophys. Acta 2013, 1832, 911-921.
77. Noble, P.W. Epithelial fibroblast triggering and interactions in pulmonary fibrosis. Eur. Respir. Rev. 2008, 17, 123-129.
78. Chen, H., Matsumoto, K., Brockway, B.L., Rackley, C.R., Liang, J., Lee, J.-H., Jiang, D., Noble, P.W., Randell, S.H., Kim, C.F., et al. Airway epithelial progenitors are region specific and show differential responses to bleomycin-induced lung injury. Stem Cell. (Dayton, OH) 2012, 30, 1948-1960.
79. Selman, M., Pardo, A. Role of epithelial cells in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006, 3, 364-372.
80. Pelaseyed, T., Bergström, J.H., Gustafsson, J.K., Ermund, A., Birchenough, G.M.H., Schütte, A., van der Post, S., Svensson, F., Rodríguez-Piñeiro, A.M., Nyström, E.E.L., et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 2014, 260, 8-20.
81. Wolters, P.J., Collard, H.R., Jones, K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 2014, 9, 157-179.
82. Camelo, A., Dunmore, R., Sleeman, M.A., Clarke, D.L. The epithelium in idiopathic pulmonary fibrosis: Breaking the barrier. Front. Pharm. 2013, 4, 173.
83. Armanios, M. Telomerase and idiopathic pulmonary fibrosis. Mutat. Res. 2012, 730, 52-58.
84. Tanjore, H., Blackwell, T.S., Lawson, W.E. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302, L721-L729.
85. Schultz, G.S., Wysocki, A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009, 17, 153-162.
86. Mercer, P.F., Chambers, R.C. Coagulation and coagulation signalling in fibrosis. Biochim. Biophys. Acta 2013, 1832, 1018-1027.
87. Sebag, S.C., Bastarache, J.A., Ware, L.B. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr. Pharm. Biotechnol. 2011, 12, 1481-1496.
88. Wynn, T.A., Ramalingam, T.R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012, 18, 1028-1040.
89. Cheresh, P., Kim, S.J., Tulasiram, S., Kamp, D.W. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta 2013, 1832, 1028-1040.
90. Bocchino, M., Agnese, S., Fagone, E., Svegliati, S., Grieco, D., Vancheri, C., Gabrielli, A., Sanduzzi, A., Avvedimento, E.V. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS ONE 2010, 5, e14003.
91. Ding, N.-H., Li, J.J., Sun, L.-Q. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr. Drug Targets 2013, 14, 1247-1356.
92. Huebener, P., Schwabe, R.F. Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim. Biophys. Acta 2013, 1832, 1005-1017.
93. Millien, V.O., Lu, W., Shaw, J., Yuan, X., Mak, G., Roberts, L., Song, L.-Z., Knight, J.M., Creighton, C.J., Luong, A., et al. Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4. Science (New York) 2013, 341, 792-796.
94. Todd, N.W., Luzina, I.G., Atamas, S.P. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5, 1-24.
95. Zoz, D.F., Lawson, W.E., Blackwell, T.S. Idiopathic pulmonary fibrosis: A disorder of epithelial cell dysfunction. Am. J. Med. Sci. 2011, 341, 435-438.
96. Kendall, R.T., Feghali-Bostwick, C.A. Fibroblasts in fibrosis: Novel roles and mediators. Front. Pharm. 2014, 5, 123.
97. Neary, R., Watson, C.J., Baugh, J.A. Epigenetics and the overhealing wound: The role of DNA methylation in fibrosis. Fibrogenesis Tissue Repair 2015, 8, 1-13.
98. Vancheri, C. Idiopathic pulmonary fibrosis and cancer: Do they really look similar? BMC Med. 2015, 13, 1-5.
99. Robinson, C.M., Watson, C.J., Baugh, J.A. Epigenetics within the matrix: A neo-regulator of fibrotic disease. Epigenetics 2012, 7, 987-993.
100. Prasad, S., Hogaboam, C.M., Jarai, G. Deficient repair response of ipf fibroblasts in a co-culture model of epithelial injury and repair. Fibrogenesis Tissue Repair 2014, 7, 7.
101. Selman, M., Pardo, A. Idiopathic pulmonary fibrosis: An epithelial/fibroblastic cross-talk disorder. Respir. Res. 2002, 3, 3.
102. Pardo, A., Selman, M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5, S9.
103. Henderson, N.C., Sheppard, D. Integrin-mediated regulation of tgfβ in fibrosis. Biochim. Biophys. Acta 2013, 1832, 891-896.
104. Jiang, D., Liang, J., Noble, P.W. Regulation of non-infectious lung injury, inflammation, and repair by the extracellular matrix glycosaminoglycan hyaluronan. Anat Rec. (Hoboken) 2010, 293, 982-985.
105. White, E.S. Lung extracellular matrix and fibroblast function. Ann. Am. Thorac. Soc. 2015, 12, S30-S33.